Bacteria injected into tumors: a new weapon against cancer?
NCT ID NCT05120596
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests a genetically modified version of the Yersinia enterocolitica bacterium, given alone or with the immunotherapy pembrolizumab, in 100 adults with advanced solid tumors that have no standard treatment options. The goal is to find a safe dose and see if the bacteria can shrink tumors. Because it is a first-in-human study, the main focus is on safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetically modified Yersinia enterocolitica bacteria (T3P-Y058-739) given alone or with pembrolizumab
- What this could lead to
- If it works, this could point toward a new way to treat advanced solid tumors by using bacteria to attack cancer cells.
- What could go wrong
- This is a very early, first-in-human trial with only 100 participants. The bacteria may cause infections or other side effects, and the treatment might not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Cancer Research UK Clinical trials; Unit Partner in CaCTUS- Cancer clinical trials Unit Scotland; Beatson West of Scotland Cancer Centre
RECRUITINGGlasgow, G12 0YN, United Kingdom
Contact
-
Centre Hospitalier Universitaire Vaudois Lausanne (CHUV)
RECRUITINGLausanne, 1011, Switzerland
Contact
-
Clinica Universidad de Navarra
RECRUITINGPamplona, Navarre, 31008, Spain
Contact
-
Clinica Universidad de Navarra
RECRUITINGMadrid, 28027, Spain
Contact
-
Hospital Clínico Universitario de Valencia (INCLIVA)
RECRUITINGValencia, 46010, Spain
Contact
-
Hospital Universitario 12 De Octubre
RECRUITINGMadrid, 28041, Spain
Contact
-
Hospital Universitario La Paz
RECRUITINGMadrid, 28046, Spain
Contact
-
Institut Catala D'oncologia
RECRUITINGL'Hospitalet de Llobregat, 08908, Spain
Contact
-
Leeds Clinical Research Facility
RECRUITINGLeeds, LS9 7TF, United Kingdom
Contact
-
Royal Marsden NHS Foundation Trust
RECRUITINGLondon, SW3 6JJ, United Kingdom
Contact
-
START Madrid-CIOCC Hospital Univ. HM Sanchinarro
RECRUITINGMadrid, 28050, Spain
Contact
-
University Hospital Bern (Inselspital)
RECRUITINGBern, 3010, Switzerland
Contact
-
University Hospital Southampton NHS Foundation Trust
RECRUITINGSouthampton, SO16 6YD, United Kingdom
Contact
-
University Hospital of Zürich (Universitätsspital Zürich)
RECRUITINGZurich, 8091, Switzerland
Contact
-
Vall d'Hebron Institute of Oncology
RECRUITINGBarcelona, 08035, Spain
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a new antibody help the immune system fight advanced cancers?
- Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.
- Can a cancer vaccine train the body to fight advanced tumors?